LNTH News and Press, Lantheus Holdings Inc. From 09/30/20

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents a...

The following slide deck was published by Lantheus Holdings, Inc. in conjunction with this Read more ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and produ...

This article series shows every month a dashboard with aggregate industry metrics in healthcare (popular ETFs in this sector: XLV , IYH , IBB , XBI , VHT , XPH ). Shortcut If you are used to this dashboard series or if you are short on time, you can skip the first paragraphs and go...

The FDA approves  Lantheus's ( LNTH -0.3% ) for VIALMIX RFID an activation device for DEFINITY injectable suspension, an intravenous ultrasound enhancing agent. More news on: Lantheus Holdings, Inc., Healthcare stocks news, Read more ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and produ...

Lantheus Holdings, Inc. (LNTH) Q2 2020 Results Earnings Conference Call July 30, 2020, 08:00 AM ET Company Participants Mark Kinarney - Senior Director, IR Mary Anne Heino - President and CEO Robert Marshall - CFO Conference Call Participants Raj Denhoy - Jefferies Larry ...

Image source: The Motley Fool. Lantheus Holdings Inc   (NASDAQ: LNTH) Q2 2020 Earnings Call Jul 30, 2020 , 8:00 a.m. ET Operator Continue reading

Lantheus (NASDAQ: LNTH ) : Q2 Non-GAAP EPS of $0.10 beats by $0.02 ; GAAP EPS of -$0.16. More news on: Lantheus Holdings, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline Worldwide revenue of $66.0 million for the second quarter 2020, representing a decrease of 23.0% from the prior year period Net loss of $7.0 ...